Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant TQB2102 in HER2-positive breast cancer
CTR20234259Phase 2Completed
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jan 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in breast cancer, sponsored by Nanjing Shunxin Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20234259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234259.